Gravar-mail: Pre-Therapeutic Total Lesion Glycolysis on [(18)F]FDG-PET Enables Prognostication of 2 Year Progression-Fee Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy